Mark is a serial supporter of growth companies with a wealth of experience of start-up and early stage businesses. He is a director of a number of health and life science companies, whose technologies range from oncology therapeutic development through to medical devices for a range of applications including the management of metabolic disease.
John joined Biofortuna in November 2016 as the Foresight Investor Director. At Foresight, John is responsible for deploying the Foresight Williams Technology EIS Fund and is a specialist investor in technology. John has worked in and managed technology investment teams at businesses such as 3i Group, Angle and Imperial Innovations, where he spent five years investing in and working with early stage technology and medtech companies, before working on his own advisory and funding business. John is a graduate of Durham University and has a MBA with Distinction from Cranfield University.
Nick is an experienced CEO with over 20 years’experience in public listed and private companies operating internationally across the life sciences, healthcare diagnostic and biotechnology industries. Prior to joining Biofortuna, Nick was CEO of Source BioScience plc, the laboratory service and products business, where he helped grow revenues five fold, delivering an enterprise valued at more than £70 million. Nick holds a PhD in Mycology and is a Chartered Accountant, qualifying with KPMG. Nick is currently Chairman of Epistem Limited, the pre-clinical and clinical development CRO.
Nick is an experienced Chief Operating Officer in the life sciences and healthcare diagnostic sectors. Prior to joining Biofortuna, Nick was COO of Source BioScience plc for ten years, expanding the operations from a single site in the UK to ten facilities worldwide, integrating multiple acquisitions. Before Source BioScience, Nick was a co-founder of the genomics services and products company Geneservice and worked for over ten years in complex genetics and genomics; initially at Oxford University and then for the MRC at the Wellcome Trust Sanger Centre. Nick qualified as a microbiologist and worked in the NHS, completing a PhD on the molecular methods used to characterise outbreaks of bacterial meningitis.
Simon has over 30 years experience in biotech working for Amersham International (now GE), ICI and AstraZeneca. Previously he was CEO of the life science company Tepnel plc (now Hologic) and Chief Executive of start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was acquired by Agilent Technologies Inc and is currently the Chairman of AIM listed Fusion Antibodies plc, an antibody engineering services provider.
Mike is a molecular biologist with over 20 years of clinical experience and a PhD in transplantation immunogenetics from Oxford and is a co-founder of Biofortuna. He has years of industrial experience in developing commercial genotyping and phenotyping products in both conventional and lyophilised formats. Mike also plays an important role in the company’s design and development of analytical software and instrumentation.
Geoff is a Fellow of the Institute of Chartered Accountants in England and Wales having qualified with PricewaterhouseCoopers and is a Chartered Tax Adviser. Geoff is an experienced Finance Director who has served on the Boards of numerous PE backed and AIM listed businesses across a wide range of sectors including healthcare, drug testing services, IT, medical testing services, manufacturing of emergency services equipment and biotech companies.
Dave is a co-founder of Biofortuna, building on his R&D experience in developing complex genotyping solutions within Dynal / Invitrogen Transplant Diagnostics division. David specialised in developing and project managing key projects in macro and microarray technologies. He has a BSc in Genetics from the University of Liverpool.
Harry has over 18 years experience in commercial and operational roles in life sciences and diagnostic businesses. Prior to joining Biofortuna Harry was Director of Operations at London Genetics, Genotyping Project Manager at DxS, and Sales Manager at Whatman. Harry graduated in Manchester where he obtained a BSc in Biological Sciences and an MSc in Biomedical Sciences followed by positions in Clinical Genetics at Northwick Park Hospital and Manchester Royal Infirmary.
Lee has over 22 years’ experience, working in large organizations and start-up companies in a variety of technical and leadership positions. Previously Lee held technical positions in Fisons Ltd, AstraZeneca Ltd, Lumitech Ltd, Cambrex Inc, Lonza and L3T. More recently Lee was the Technical Team Leader for Swiss Precision Diagnostics Ltd (JV between Alere and P&G) responsible for the development of the Clearblue® product range and Head of Product Development at Microvisk Ltd responsible for CE-Marking the world’s first MEM’s based POC IVD. Lee has a BSc in Biochemistry from Nottingham Trent University and specializes in enzymatic immunoassay and molecular IVD development from concept to commercialization.